weighting_scheme,lifespan_efficacy,healthspan_efficacy,mechanism_conservation,human_trial_evidence,safety_tolerability,biomarker_availability,cost_accessibility,description
baseline,0.2,0.1,0.1,0.2,0.2,0.1,0.1,Balanced weighting prioritizing human safety and evidence while preserving preclinical impact
regulator_focused,0.1,0.1,0,0.3,0.4,0,0.1,Emphasizes safety profile and human evidence for regulatory approval pathways
investor_focused,0.4,0.2,0,0.1,0.1,0.1,0.1,Prioritizes preclinical efficacy and measurable biomarkers for investment decisions
patient_focused,0.1,0.2,0,0.25,0.3,0,0.15,Balances safety with clinical evidence and affordability for patient accessibility
